Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online March 16, 2011.
Article Versions
- You are currently viewing a Latest version of this article (March 16, 2011 - 10:37).
- View the most recent version of this article
Copyright & Usage
© 2011 The Journal of Rheumatology
Author Information
- Gunnar Tomasson,
- Michael Lavalley,
- Kahraman Tanriverdi,
- Javier D. Finkielman,
- John C. Davis Jr.,
- Gary S. Hoffman,
- W. Joseph McCune,
- E. William St. Clair,
- Ulrich Specks,
- Robert Spiera,
- John H. Stone,
- Jane E. Freedman and
- Peter A. Merkel, for the Wegener's Granulomatosis Etanercept Trial Research Group
- From the Boston University (BU) School of Medicine, and Massachusetts General Hospital, Boston, Massachusetts; Mayo Clinic, Rochester, Minnesota; Genentech Corporation, South San Francisco, and the University of California at San Francisco, California; Cleveland Clinic, Cleveland, Ohio; University of Michigan, Ann Arbor, Michigan; Duke University, Durham, North Carolina; and the Hospital for Special Surgery, New York, New York, USA.
Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Multidisciplinary Clinical Research Center grant P60 AR047785. The Wegener’s Granulomatosis Etanercept Trial (WGET) was supported by the NIAMS, US National Institutes of Health (NIH) N01-AR92240, and the Office of Orphan Products, US Food and Drug Administration (grant FD-R-001652), General Clinical Research Center grants M01-RRO-00533 (Boston University), M01-RRO-0042 (The University of Michigan), MO1-RR-30 (Duke University), and M01-RRO-2719 (Johns Hopkins University School of Medicine), from the National Center for Research Resources/NIH. Drs. Stone, Merkel, and St. Clair were supported by NIAMS grants K24 AR049185-01, K24 AR2224-01A1, and K24 AR02126-04. Dr. Freedman’s laboratory is supported by US National Heart, Lung, and Blood Institute grants R01 HL 083801 and R01 HL087201.
G. Tomasson, MD; M. LaValley, PhD; K. Tanriverdi, PhD, Boston University School of Medicine; J.D. Finkielman, MD, Mayo Clinic; J.C. Davis Jr, MD, MPH, Genentech Corporation and University of California at San Francisco; G.S. Hoffman, MD, MS, Cleveland Clinic, Co-chair, Wegener’s Granulomatosis Etanercept Trial Research Group; W.J. McCune, MD, University of Michigan; E.W. St. Clair, MD, Duke University; U. Specks, MD, Mayo Clinic; R. Spiera, MD, Hospital for Special Surgery; J.H. Stone, MD, MPH, Massachusetts General Hospital, Chair, Wegener’s Granulomatosis Etanercept Trial Research Group; J.E. Freedman, MD; P.A. Merkel, MD, MPH, Boston University School of Medicine.
Address correspondence to Dr. P.A. Merkel, Section of Rheumatology and the Clinical Epidemiology Unit, Vasculitis Center, E533, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA. E-mail: pmerkel@bu.edu
Accepted for publication January 26, 2011.